UTHR Q2 2021 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$447M+23.3% YoY

Gross Profit

$409M91.7% margin

Operating Income

$222M49.8% margin

Net Income

$173M38.7% margin

EPS (Diluted)

$3.65

QoQ Revenue Growth

+17.8%

Cash Flow

Operating Cash Flow

$148M

Free Cash Flow

$132M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$4.8B

Total Liabilities

$1.2B

Stockholders' Equity

$3.6B

Cash & Equivalents

$942M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$447M	$362M	+23.3%
Gross Profit	$409M	$336M	+21.8%
Operating Income	$222M	$141M	+58.1%
Net Income	$173M	$107M	+61.2%

Revenue Segments

Tyvaso

$154M34%

Remodulin

$140M31%

Orenitram

$76M17%

Unituxin

$53M12%

Adcirca

$24M5%

Geographic Segments

UNITED STATES

$412M92%

European Union And Others

$35M8%